OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lee on Immunotherapy's Future in RCC

February 3rd 2017

Chung-Han (Joe) Lee, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy in the treatment landscape of renal cell carcinoma.

Dr. Sanft on Sequencing of Treatments for HER2+ Breast Cancer

February 3rd 2017

Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

Dr. Petrylak on FDA Approval of Nivolumab in Bladder Cancer

February 3rd 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCC

February 3rd 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.

Dr. Socinski on Challenges Facing Immunotherapy Combinations

February 3rd 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).

Dr. Pollack on the Potential Impact of Radiomics on the Sarcoma Treatment Landscape

February 3rd 2017

Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.

Dr. Beaupre on Ibrutinib in Marginal Zone Lymphoma

February 2nd 2017

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial exploring the efficacy of ibrutinib in patients with marginal zone lymphoma.

Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC

February 2nd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer

February 2nd 2017

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.

Dr. Neelapu on Next Steps With KTE-C19 in Lymphoma

February 2nd 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps with KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Dr. Giralt on Future of Transplant in Multiple Myeloma

February 2nd 2017

Sergio Giralt, MD, a professor of Medicine at Memorial Sloan Kettering Cancer Center, discusses the future role of transplantation in patients with multiple myeloma as well as other hematologic malignancies.

Dr. Muggia on the GOG 252 Trial in Ovarian Cancer

February 2nd 2017

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses the GOG 252 trial, which looked at the use of intravenous versus intraperitoneal chemotherapy in the treatment of patients with ovarian cancer.

Dr. Brufsky on the COLET Trial for Triple-Negative Breast Cancer

February 2nd 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the COLET trial combining cobimetinib (Cotellic) and paclitaxel (Abraxane) as a treatment for patients with triple-negative breast cancer (TNBC).

Dr. Gong on Adverse Events of TKI VEGF-Directed Therapy in RCC

February 2nd 2017

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).

Dr. Abida on Future of Hormonal Therapy in Prostate Cancer

February 2nd 2017

Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

Dr. Concepcion on Transition to Value-Based Model in Urology

February 1st 2017

Raoul Concepcion, MD, director of the Comprehensive Prostate Center, discusses the impending transition to a value-based model in urology.

Dr. Weiss on Disease-Control Rate of Immunotherapy for Lung Cancer

February 1st 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

Dr. Goy on the Role of Immunotherapy in Mantle Cell Lymphoma

February 1st 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses immunotherapy agents currently being evaluated in the treatment of patients with mantle cell lymphoma.

Dr. Royce on Progress Being Made in HER2+ Positive Breast Cancer

February 1st 2017

Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

Dr. Lin on Chemoradiation in Elderly Patients with Esophageal Cancer

February 1st 2017

Steven H. Lin, MD, PhD, associate professor at The University of Texas MD Anderson Center, discusses study of chemoradiation in elderly patients with esophageal cancer.